Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
4D Molecular Therapeutics Inc
(NQ:
FDMT
)
25.15
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 4D Molecular Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
BMO Capital Markets Says 4D Molecular Could Be 'Attractive Acquisition Target'
January 30, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
Via
Benzinga
4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs
January 09, 2023
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Expert Ratings for 4D Molecular Therapeutics
November 18, 2022
Via
Benzinga
How Is The Market Feeling About 4D Molecular Therapeutics?
December 15, 2022
4D Molecular Therapeutics's (NASDAQ:FDMT) short percent of float has fallen 15.19% since its last report. The company recently reported that it has 2.29 million shares sold short, which is 8.82% of all...
Via
Benzinga
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
November 23, 2022
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference
November 21, 2022
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall Street
November 20, 2022
Recent analyst upgrades suggest these stocks can triple your money or better.
Via
The Motley Fool
HC Wainwright Creates Bullish Pitch On 4D Molecular Citing 'Broader Systemic Potential'
November 18, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
November 18, 2022
Upgrades
Via
Benzinga
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
November 18, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough."
Via
Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
November 17, 2022
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
Via
Benzinga
Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday
November 16, 2022
Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday.
Via
Benzinga
Sea, UiPath, J&J Snack Foods And Other Big Gainers From Tuesday
November 16, 2022
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite gaining more than 150 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 67 Stocks Moving In Tuesday's Mid-Day Session
November 15, 2022
Gainers SenesTech, Inc. (NASDAQ: SNES) shares surged 91.7% to $0.2751. SenesTech reported a 1-for-20 reverse stock split.
Via
Benzinga
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected
November 15, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 15, 2022
Gainers Azenta (NASDAQ:AZTA) shares rose 32.5% to $61.74 during Tuesday's pre-market session. The company's market cap stands at $4.6 billion. As per the news, the Q4 earnings report came out...
Via
Benzinga
4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial
November 14, 2022
Via
Benzinga
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
November 14, 2022
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
November 14, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
Via
Benzinga
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
November 10, 2022
4D Molecular Therapeutics to host a conference call on November 14th, 8:00 am E.T.
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results
November 09, 2022
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
November 03, 2022
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
October 27, 2022
Gainers
Via
Benzinga
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022
October 26, 2022
4D Molecular Therapeutics to host a conference call on November 3rd, 4:30 pm E.T.
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness
September 29, 2022
Kiora Pharmaceuticals Inc. (NASDAQ: KPRX), a pharmaceutical company specializing in treating eye diseases, is moving its drug candidate KIO-301 into a Phase 1b study in the third quarter of this year.
Via
Benzinga
Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket
September 29, 2022
Gainers Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European...
Via
Benzinga
4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer
September 27, 2022
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
August 15, 2022
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.